title: Ferucarbotran expands area treated by radiofrequency ablation in rabbit livers.
abstract: OBJECTIVE
  Several studies have examined the factors involved with expansion of the coagulation volume following radiofrequency ablation (RFA). Ferucarbotran contains superparamagnetic iron oxide that generates heat in a radiofrequency electric field and may have an effect on the area affected by RFA. We attempted to determine whether ferucarbotran administration expands radiofrequency-ablated volume using a rabbit model.
  
  
  METHODS
  A total of 15 male Japanese white rabbits (16 weeks old) were used and divided into three groups of five each. A 1-mL saline solution was given intravenously into a dorsal ear vein in the control group, whereas 1 mL ferucarbotran solution (0.016 mL/kg bodyweight) was given to the common-dose group and 1 mL of a twofold concentrated ferucarbotran solution (0.032 mL/kg bodyweight) was given to the high-dose group. RFA was performed with a cool-tip electrode 4 h after the administration and immediately thereafter the rabbits were killed, and the volume of the ablated area measured using magnetic resonance imaging (MRI). Following the MRI analysis, the rabbit's livers were resected, and the maximum short axis diameter of the ablated area in each was measured.
  
  
  RESULTS
  None of the rabbits died during the RFA procedure. The volume of the ablated area estimated on MR images in the ferucarbotran-administered groups was larger than that in the control group. Further, our macroscopic assessment showed that the maximum short axis diameter had a tendency to increase with ferucarbotran administration.
  
  
  CONCLUSIONS
  Ferucarbotran may expand the area treated by RFA.
authors.affiliation: Division of Gastrointestinal Endoscopy, Shimane University Hospital, Izumo, Shimane, Japan. miyake@med.shimane-u.ac.jp
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Miyake
authors.forename: Shuichi
authors.initials: S
authors.lastname: Sato
authors.forename: Eisuke
authors.initials: E
authors.lastname: Okamoto
authors.forename: Junichi
authors.initials: J
authors.lastname: Ishine
authors.forename: Naoki
authors.initials: N
authors.lastname: Oshima
authors.forename: Takane
authors.initials: T
authors.lastname: Azumi
authors.forename: Tomoko
authors.initials: T
authors.lastname: Mishiro
authors.forename: Koichiro
authors.initials: K
authors.lastname: Furuta
authors.forename: Shunji
authors.initials: S
authors.lastname: Ishihara
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Adachi
authors.forename: Yuji
authors.initials: Y
authors.lastname: Amano
authors.forename: Yoshikazu
authors.initials: Y
authors.lastname: Kinoshita
mesh_terms: D000818:Animals; D017115:Catheter Ablation; D003911:Dextrans; D004305:Dose-Response Relationship, Drug; D052203:Ferrosoferric Oxide; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage / Q000494:pharmacology*; D008099:Liver / Q000187:drug effects* / Q000473:pathology / Q000601:surgery*; D008279:Magnetic Resonance Imaging; D058185:Magnetite Nanoparticles; D008297:Male; D010087:Oxides / Q000008:administration & dosage / Q000494:pharmacology*; D011817:Rabbits
chemical_list: D003911:Dextrans; D058185:Magnetite Nanoparticles; D010087:Oxides; D007501:Iron; C065507:ferumoxides; D052203:Ferrosoferric Oxide